Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,912.80
(
0.76%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
-2.31%
)
Bitcoin
77,944.21
(
2.12%
)
News Focus
News Focus
Post# of 257482
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

n4807g

Send PM Follow Ignore
Followers 42
Posts 33948
Boards Moderated 0
Alias Born 07/08/2003

n4807g

Member Level

Re: None

Wednesday, 05/17/2017 8:27:51 AM

Wednesday, May 17, 2017 8:27:51 AM

Post# of 257482
FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure
https://finance.yahoo.com/news/fda-grants-fast-track-designation-050000262.html

Looking better with each news release. I thought C-Cure was dead. Will be interesting to see if they can find a partner. If they do, and the terms are favorable, CYAD share price (today) looks like a bargain.

At this price an acquisition seems like a reasonable option.

“A bank would never get away with what the Department of Education is doing.”

Sheila Bair

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today